EyePoint Pharmaceuticals, Inc. — Director's Dealing 2026

Jan 6, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2026-01-02

Reporting Person: Lurker Nancy (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-05	Common Stock	M	12666.00	$0.00	Acquired	219213.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-02	Stock Option (Right to Buy)	$17.48	A	40000.00	Acquired	2036-01-02	Common Stock (40000.00)	Direct
2026-01-05	Restricted Stock Units	$0.00	M	12666.00	Disposed		Common Stock (12666.00)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	126889.00	Indirect

Footnotes

F1: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F2: The restricted stock units vest in three ratable annual installments beginning January 5, 2025.